0000000000377225

AUTHOR

Marisol Huerta Alvaro

showing 3 related works from this author

Final results of neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in advanced pancreatic cancer patients treated with Nab-paclitaxel plus …

2016

e15737Background: Pancreatic cancer is the ninth most common cancer and the forth cause of cancer-related mortality worldwide. New regimens have increased overall survival, but it still remains ext...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseGemcitabineOncologyPancreatic cancerInternal medicineImmunologymedicineOverall survivalNeutrophil to lymphocyte ratiobusinesshuman activitieshealth care economics and organizationsNab-paclitaxelmedicine.drugJournal of Clinical Oncology
researchProduct

The actual management of colorectal liver metastases

2020

Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease. There have been great improvements in the management of CRLM during the last decades. The combination of modern chemotherapeutic and biological systemic treatments with aggressive surgical resection strategies is currently the base for the treatment of patients considered unresectable until few years ago. Furthermore, several new treatments for the local control of CRLM have been developed and are now part of the arsenal of multidisciplinary teams for the treatment of these complex patients. The aim of this review was to s…

ReoperationSurgical resectionmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerLeucovorinDisease030230 surgery03 medical and health sciencesHepatic Artery0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHepatectomyHumansInfusions Intra-ArterialMedicineMicrowavesRadiofrequency Ablationbusiness.industryGeneral surgeryLiver NeoplasmsMargins of ExcisionPrognosismedicine.diseaseLiver TransplantationElectroporation030220 oncology & carcinogenesisCamptothecinSurgeryFluorouracilColorectal NeoplasmsbusinessMinerva Chirurgica
researchProduct

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” S…

2020

: Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at evaluating the effectiveness of second-line Bevacizumab- and Aflibercept-based treatments after an anti-EGFR based first-line regimen. Clinical outcomes measured were: objective response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events (AEs) profiles. Results: From February 2011 to October 2019, 277 consecutive mCRC patients received Bevacizumab-based (228,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerAnti-angiogenicCetuximablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicinePanitumumabProgression-free survivalAfliberceptRAS wild-type mCRCPerformance statusCetuximabbusiness.industryPanitumumabanti-angiogenicsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBevacizumabRegimen030104 developmental biologyOncology030220 oncology & carcinogenesissecond-line treatmentbusinessAfliberceptaflibercept; anti-angiogenics; bevacizumab; cetuximab; panitumumab; ras wild-type mcrc; second-line treatmentmedicine.drugCancers
researchProduct